A study to investigate the safety, tolerability, and pharmacokinetics (PK) of oral AZD6793 in healthy and Chronic Obstructive Pulmonary Disease participants, to assess the relative oral bioavailability between two formulations, and the food effect on the PK of AZD6793 compared to fasting state.

Trial Identifier: D7860C00001
Sponsor: AstraZeneca
Start Date: December 2022
Primary Completion Date: October 2024
Study Completion Date: October 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Harrow, GB, HA1 3UJ
GB Wythenshawe, GB, M23 9QZ